In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality

被引：2
|
作者：
Kelsey, Michelle D. [1 ]
Newby, L. Kristin [1 ]
机构：
[1] Duke Univ, Durham, NC 27710 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2022年 / 175卷 / 03期
关键词：
D O I：
10.7326/J22-0003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：JC26 / JC26
页数：1
相关论文
共 50 条
  • [1] In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
    Tanner, Michael
    [J]. ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) : JC67 - JC67
  • [2] Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
    Hu, Jia-Chian
    Shao, Shih-Chieh
    Tsai, Daniel Hsiang-Te
    Chuang, Albert Tzu-Ming
    Liu, Kuan-Hung
    Lai, Edward Chia-Cheng
    [J]. JAMA NETWORK OPEN, 2024, 7 (03) : E240946
  • [3] SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
    Patel, Tejas
    [J]. ANNALS OF INTERNAL MEDICINE, 2023, 176 (03) : JC27 - JC27
  • [4] GLP-1 RA and SGLT2 Inhibitors In Harmony for Organ Protection
    Aroda, Vanita R.
    Billings, Liana K.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (06) : 526 - 528
  • [5] SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
    Cervantes, Carlos Escobar
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 507 - 508
  • [6] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
    Nauck, Michael A.
    Meier, Juris J.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (12): : 963 - 964
  • [7] SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
    De Block, Christophe
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 349 - 352
  • [8] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    [J]. AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
  • [9] SGLT2 inhibitors vs. GLP-1 agonists: Comparative progression of renal disease
    Stevens, Lauren
    Bowe, Andy
    Schwab, Phil
    Tindal, Michael
    Bloomfield, Andrea
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 110 - 110
  • [10] Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
    Jha, Kunal K.
    Adhikari, Rishav
    Tasdighi, Erfan
    Osuji, Ngozi
    Rajan, Tanuja
    Blaha, Michael J.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (12) : 925 - 937
12345